Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 May;17(5):565–572. doi: 10.1111/j.1365-2125.1984.tb02391.x

Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.

H L Elliott, K McLean, P A Meredith, D J Sumner, J L Reid
PMCID: PMC1463449  PMID: 6145440

Abstract

Medroxalol, a new drug which has been reported to possess both alpha- and beta-adrenoceptor antagonist properties, was compared with labetalol in single dose studies in normotensive males. Oral doses of 400 mg of each drug significantly reduced blood pressure, both supine and erect, without significant changes in heart rate. The chronotropic and diastolic depressor responses to isoprenaline were significantly antagonised by both drugs, for at least 6-8 h after drug administration. Medroxalol was associated with significantly greater beta-adrenoceptor antagonism than labetalol. There was no significant antagonism by either drug of the pressor response to noradrenaline. However, in a sub-group of subjects the responses to the selective alpha 1-adrenoceptor agonist, phenylephrine, were consistent with modest alpha 1-adrenoceptor antagonism. This was significant only for labetalol. The ratios of beta 1- to alpha 1-adrenoceptor antagonism as calculated from the relative shifts of the isoprenaline and phenylephrine dose-response curves, were 3 to 1 for labetalol and about 7 to 1 for medroxalol.

Full text

PDF
565

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brittain R. T., Levy G. P. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):681–684. [PubMed] [Google Scholar]
  2. Da Prada M., Zürcher Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci. 1976 Oct 15;19(8):1161–1174. doi: 10.1016/0024-3205(76)90251-4. [DOI] [PubMed] [Google Scholar]
  3. Dage R. C., Cheng H. C., Woodward J. K. Cardiovascular properties of medroxalol, a new antihypertensive drug. J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):299–315. doi: 10.1097/00005344-198103000-00009. [DOI] [PubMed] [Google Scholar]
  4. Dage R. C., Hsieh C. P., Spedding M. Vasodilation by medroxalol mediated by beta 2-adrenergic receptor stimulation. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):143–150. doi: 10.1097/00005344-198301000-00022. [DOI] [PubMed] [Google Scholar]
  5. Elliott H. L., McLean K., Sumner D. J., Meredith P. A., Reid J. L. Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers. Clin Pharmacol Ther. 1981 Mar;29(3):303–309. doi: 10.1038/clpt.1981.40. [DOI] [PubMed] [Google Scholar]
  6. Elliott H. L., Meredith P. A., Sumner D. J., Reid J. L. Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. Br J Clin Pharmacol. 1984 May;17(5):573–578. doi: 10.1111/j.1365-2125.1984.tb02392.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Farmer J. B., Kennedy I., Levy G. P., Marshall R. J. Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors. Br J Pharmacol. 1972 Aug;45(4):660–675. doi: 10.1111/j.1476-5381.1972.tb08125.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Frishman W. H., Strom J. A., Kirschner M., Poland M., Klein N., Halprin S., LeJemtel T. H., Kram M., Sonnenblick E. H. Labetalol therapy in patients with systemic hypertension and angina pectoris: effects of combined alpha and beta adrenoceptor blockade. Am J Cardiol. 1981 Nov;48(5):917–928. doi: 10.1016/0002-9149(81)90359-3. [DOI] [PubMed] [Google Scholar]
  9. Jaillon P., Weissenburger J., Biour M., Cheymol G., Haegele K., Schechter P. J., Koch-Weser J. beta- and alpha-Adrenoceptor antagonism by medroxalol in healthy volunteers: relationship to dose and plasma concentration. J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):705–713. doi: 10.1097/00005344-198209000-00003. [DOI] [PubMed] [Google Scholar]
  10. Joekes A. M., Thompson F. D. Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):789–793. [PubMed] [Google Scholar]
  11. McKenna D. H., Corliss R. J., Sialer S., Zarnstorff W. C., Crumpton C. W., Rowe G. G. Effect of propranolol on systemic and coronary hemodynamics at rest and during simulated exercise. Circ Res. 1966 Sep;19(3):520–527. doi: 10.1161/01.res.19.3.520. [DOI] [PubMed] [Google Scholar]
  12. Meredith P. A., McSharry D., Elliott H. L., Reid J. L. The determination of labetalol in plasma by high-performance liquid chromatography using fluorescence detection. J Pharmacol Methods. 1981 Dec;6(4):309–314. doi: 10.1016/0160-5402(81)90070-x. [DOI] [PubMed] [Google Scholar]
  13. Richards D. A., Prichard B. N. Concurrent antagonism of isoproterenol and norepinephrine after labetalol. Clin Pharmacol Ther. 1978 Mar;23(3):253–258. doi: 10.1002/cpt1978233253. [DOI] [PubMed] [Google Scholar]
  14. Richards D. A., Tuckman J., Prichard B. N. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol. 1976 Oct;3(5):849–855. doi: 10.1111/j.1365-2125.1976.tb00637.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rosei E. A., Trust P. M., Brown J. J., Lever A. F., Robertson J. I. Letter: Intravenous labetalol in severe hypertension. Lancet. 1975 Nov 29;2(7944):1093–1094. doi: 10.1016/s0140-6736(75)90470-5. [DOI] [PubMed] [Google Scholar]
  16. Starke K., Endo T., Taube H. D. Relative pre- and postsynaptic potencies of alpha-adrenoceptor agonists in the rabbit pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol. 1975;291(1):55–78. doi: 10.1007/BF00510821. [DOI] [PubMed] [Google Scholar]
  17. Sumner D. J., Elliott H. L., Reid J. L. Analysis of the pressor dose response. Clin Pharmacol Ther. 1982 Oct;32(4):450–458. doi: 10.1038/clpt.1982.188. [DOI] [PubMed] [Google Scholar]
  18. Sybertz E. J., Sabin C. S., Pula K. K., Vliet G. V., Glennon J., Gold E. H., Baum T. Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927. J Pharmacol Exp Ther. 1981 Aug;218(2):435–443. [PubMed] [Google Scholar]
  19. Vincent J., Elliott H. L., Meredith P. A., Reid J. L. Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol. 1983 Jun;15(6):719–725. doi: 10.1111/j.1365-2125.1983.tb01556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES